A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Clinical trial NCT04640077 · COMPLETED

Trial details

NCT number: NCT04640077
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Cognitive Impairment

Start date: 2020-11-23
Primary completion: 2024-02-27
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.